Molecular Devices, MIMETAS Sign Co-marketing Agreement
In a move to serve customers with ready-to-use solutions for organ-on-a-chip model development and analysis, MIMETAS and Molecular Devices will combine marketing efforts on the OrganoPlate® organ-on-a-chip platform and ImageXpress® Micro Confocal high-content imaging systems. This agreement was announced today at the SLAS2017 conference in Washington.
“OrganoPlates® are designed for ease-of-handling at any throughput, and provide unsurpassed physiological relevance,” said Jos Joore, Managing Director of MIMETAS, “As such, they are perfectly suited for the high-content imaging systems from Molecular Devices. We have been using their equipment in our internal R&D with great success. With ready-to-use protocols and methods for OrganoPlates®, the ImageXpress Micro portfolio is positioned to fully unleash the potential of OrganoPlates®.”
At Molecular Devices, Sarah Vargas-Hurlston, Director of Marketing comments, “We are excited to enter into this marketing collaboration with MIMETAS. Their organ-on-a-chip platform has unique capabilities and a proven fit with our ImageXpress Micro systems. At Molecular Devices, we value MIMETAS’s approach to offer turnkey solutions to customers which aligns with our continual focus to provide better support for customer applications. Together, we offer a solution with unprecedented capabilities in a rapidly developing organ-on-a-chip market.”
Freedom of Information Request Reveals Benefits of Blocked MS DrugNews
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).READ MORE
Blood-vessel-on-a-Chip Models Vascular Barrier FunctionNews
A newly developed human blood-vessel-on-a-chip models the vascular barrier and reveals a new cell migration-based mechanism for fibrotic diseases.READ MORE